Clinical Nuclear Medicine

Skip Navigation LinksHome > September 2013 - Volume 38 - Issue 9 > New Treatment Option: 223Ra Chloride, the First Approved Un...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182a2dd53
Interesting Images

New Treatment Option: 223Ra Chloride, the First Approved Unsealed α-Emitting Radiopharmaceutical

Colletti, Patrick M. MD

Collapse Box


Abstract: A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases. After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration–approved unsealed α-emitting radiopharmaceutical.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.